Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Beam Therapeutics Inc (NQ: BEAM ) 23.50 +0.09 (+0.38%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Beam Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. September 26, 2024 Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. Via Investor's Business Daily Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) September 11, 2024 Via Benzinga A Closer Look at 5 Analyst Recommendations For Beam Therapeutics August 22, 2024 Via Benzinga Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating August 14, 2024 William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1... Via Benzinga 3 Gene Editing Stocks with Potential to Transform Medicine August 09, 2024 Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. Via InvestorPlace BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 06, 2024 BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Expert Ratings For Beam Therapeutics April 23, 2024 Via Benzinga Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results August 06, 2024 From Beam Therapeutics Via GlobeNewswire ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio? July 28, 2024 Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% Via Benzinga IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday July 25, 2024 Via Benzinga Beam Therapeutics Stock Earns RS Rating Jump To 85 July 24, 2024 On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. Via Investor's Business Daily Why Is Conn’s (CONN) Stock Down 36% Today? July 24, 2024 Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing. Via InvestorPlace Topics Bankruptcy Exposures Financial Legal Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40 July 24, 2024 Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock. Via InvestorPlace Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday July 23, 2024 Via Benzinga 3 Gene Editing Stocks Shaping the Future of Medicine July 22, 2024 Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions Via InvestorPlace Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast July 18, 2024 Via Benzinga Beam Therapeutics Announces Transition of Chief Financial Officer July 15, 2024 From Beam Therapeutics Via GlobeNewswire The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024 July 09, 2024 Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. Via InvestorPlace 3 Stocks With the Potential to 10X Your Money July 09, 2024 These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost. Via InvestorPlace FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals July 04, 2024 Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. Via InvestorPlace Exposures Product Safety 3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030 July 03, 2024 These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever. June 27, 2024 The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects. Via InvestorPlace Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) June 26, 2024 From Beam Therapeutics Via GlobeNewswire Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease June 14, 2024 From Beam Therapeutics Via GlobeNewswire Beam Therapeutics to Participate in Jefferies Global Healthcare Conference May 30, 2024 From Beam Therapeutics Via GlobeNewswire Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress May 14, 2024 From Beam Therapeutics Via GlobeNewswire Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine May 09, 2024 These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. Via InvestorPlace Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference May 08, 2024 From Beam Therapeutics Via GlobeNewswire BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 07, 2024 BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results May 07, 2024 From Beam Therapeutics Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.